BioRestorative Therapies Inc
BRTX
$1.27
Closing
▼-5.93%
1D
▼-25.73%
YTD
Market cap
$8.60M
52 week high
$7.13
52 week low
$1.21
Volume
7,102
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$8.60M
Analysts' Rating
BUY
Price Target (Mean)
12.5
Total Analysts
2
P/E
Operating Margin
-10112.18%
Beta
Revenue Growth (Annual)
160.43%
52 week high
$7.13
52 week low
$1.21
Div. Yield
%
EPS Annual Growth
-15.58
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
BioRestorative Therapies, Inc. is a clinical-stage company engaged in developing therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells (MSCs), collected from the patient’s bone marrow. BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat)-derived stem cells (BADSC) to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
